Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Vorinostat is currently being evaluated in clinical trials in a shock and kill approach to cure HIV. Transcriptomic and proteomic profiling of Vorinostat in primary CD4 T cells has identified noteworthy off-target effects, subject-to-subject variation, as well as biomarkers that may be monitored to confirm compound exposure.
